Visualitza per autor "Vergote, Ignace"
Ara mostrant els elements 1-4 d 4
-
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer
Oaknin Benzaquen, Ana Mazaltob; Monk, Bradley J.; de Melo, Andreia Cristina; Kim, Yong-Man; Lisyanskaya, Alla; Vergote, Ignace (Elsevier, 2022-10) -
Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
ray coquard, isabelle; Lorusso, Domenica; OAKNIN, ANA; Cibula, David; Vergote, Ignace; Van Gorp, Toon (Taylor & Francis, 2023) -
Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Santin, Alessandro; González-Martin, Antonio; Moore, Kathleen N; Oaknin Benzaquen, Ana Mazaltob; Romero, Ignacio; Vergote, Ignace (BMJ, 2023-04) -
Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment
Vergote, Ignace; Hirsch, Fred R.; Hagemann, Carsten; Miller, David; Macarulla, Teresa (MDPI, 2023-01-19)